Quantitative assessment of patients with rheumatic diseases requires a pooled index of several measures,^[@R1]^ as no single measure can serve as a "gold standard" for all individual patients.^[@R2]^ Over the last 3 decades, many disease-specific self-report questionnaires have been developed to assess different rheumatic diseases.^[@R2]^ In patients with ankylosing spondylitis (AS), disease-specific indices include the Bath AS Disease Activity Index (BASDAI),^[@R3]^ Bath AS Functional Index (BASFI),^[@R4]^ AS Disease Activity Score (ASDAS) of the SpondyloArthritis International Society,^[@R5]^ and Bath AS Metrology Index (BASMI).^[@R5],[@R6]^ These indices are widely used in clinical trials, other clinical research, and a few clinical settings, but not in most routine care in busy clinical settings. Indeed, the only quantitative data found in the medical records of most patients with AS who receive care from most rheumatologists are laboratory tests, which often are not available at the time of the visit and provide limited information in many patients.^[@R5]^

It is relatively simple in busy clinical settings for a receptionist to present a self-report questionnaire to each patient to complete at each visit.^[@R7]^ However, it is not feasible in most such settings to arrange for different patients with different diagnoses to complete different disease-specific questionnaires, such as a BASDAI in AS, Health Assessment Questionnaire in rheumatoid arthritis (RA),^[@R8]^ Western Ontario Questionnaire in osteoarthritis,^[@R9]^ and other indices in other rheumatic diseases.^[@R10]^ Furthermore, new patients without a diagnosis, or patients in whom a definitive diagnosis has not been established, could benefit from availability of a simple questionnaire to help support clinical decisions.^[@R11]^

A Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data 3 (MDHAQ/RAPID3)^[@R10],[@R12],[@R13]^ was developed from the Health Assessment Questionnaire over many years in a routine clinical setting and administered to all patients with all rheumatic diseases as a continuous quality improvement activity to improve care.^[@R12]^ The MDHAQ/RAPID3 includes scores for physical function, pain, global estimate of status, fatigue, self-report joint count, symptom checklist, and recent medical history. The MDHAQ/RAPID3 has proven useful and informative in regard to patients with many rheumatic diseases, including AS.^[@R10],[@R13]^ However, these reports did not include formal comparisons of RAPID3 scores with scores on AS-specific indices.

Three recent reports indicated highly significant correlations of BASDAI with RAPID3,^[@R14]--[@R16]^ suggesting that both questionnaires provide similar information. In this report, we present cross-sectional comparisons of RAPID3 with BASDAI, BASFI, ASDAS, and BASMI, collected prospectively in 85 Korean patients with AS in a routine care setting.

PATIENTS AND METHODS
====================

Study Patients
--------------

A cross-sectional study was performed in 85 patients who were seen in a usual rheumatology outpatient clinic setting in Daegu, Korea, between May 2012 and July 2012, and who received a diagnosis of AS according to the modified New York criteria.^[@R5]^ The study was reviewed and approved by the ethical review board of the institute prior to its initiation, and written informed consent was received from every patient prior to enrollment. Patients were excluded from the study if they were younger than 18 years and had another rheumatic disease in addition to AS.

Collection of Measures
----------------------

Each patient seen in the clinic, with any diagnosis, completed a Korean version of MDHAQ, which was translated and validated by Lee et al.^[@R17]^ Each patient with AS also completed a BASDAI and BASFI. An ASDAS and BASMI were recorded by a health professional, either a metrologist or rheumatologist.

RAPID3 is scored on the MDHAQ as the 0- to 30-point sum of three 0- to 10-point patient-reported measures: physical function, pain, and patient global estimate of status.^[@R7]^ Other measures were scored as described in the literature^[@R5]^ (but not included in this report). BASDAI includes 6 measures: fatigue, back pain, pain and swelling of peripheral joints, pain of enthesis, degree of morning stiffness, and duration of morning stiffness.^[@R3],[@R5]^ BASFI includes 10 queries concerning physical function, scored as integers from 1 ("easy") to 10 ("impossible") on a Likert scale.^[@R4]^ ASDAS-ESR (erythrocyte sedimentation rate) or ASDAS-CRP (C-reactive protein) are calculated according to a formula that includes patient global status, spinal pain, spinal stiffness, fatigue, physical function, spinal mobility, and acute-phase reactant (ESR or CRP).^[@R5]^ BASMI includes 6 measures: occiput wall distance, modified Schober test, lateral spinal flexion, chest expansion, cervical rotation, and intermalleolar distance.^[@R6]^

Statistical Analysis
--------------------

Statistical analyses were performed using Stata 12.1 for Windows (College Station, TX). The Shapiro-Wilk W test was used to identify normality of distribution in the study population. Wilcoxon rank-sum test and Spearman correlations were computed for each individual measure and total scores in the composite indices, including deletion of pain scores from each index. Patients were classified for disease activity/severity according to BASDAI (≥4 active vs \<4 inactive), ASDAS (≥1.3 active vs \<1.3 inactive), and RAPID3 categories that have been developed for RA: more than 12, high; 6.1 to 12, moderate; 3.1 to 6, low severity (the term "severity" is used, as self-report scores do not necessarily distinguish activity from damage); and 0 to 3, remission. It is noted that these categories were developed in comparison to the Disease Activity Score in 28 Joints (DAS28)^[@R19]^ for RA^[@R20]^ and have not been validated in AS, although they may be applicable to other rheumatic diseases.^[@R13],[@R21]--[@R23]^ Cross tabulations, κ tests, and scatter plots were used to analyze statistical significance of possible associations between RAPID3, BASDAI, and ASDAS.

RESULTS
=======

The 85 patients studied included 65 (77%) who were male. Median age was 38.7 years; disease duration, 7.0 years; body mass index, 23.8 kg/m^2^; level of formal education, 14.0 years; and HLA-B27 positivity, 94.1% (Table [1](#T1){ref-type="table"}). These data appear typical for an AS patient cohort.

###### 

Demographic and Clinical Characteristics of Study Patients

![](rhu-21-300-g001)

RAPID3 scores were correlated significantly with BASDAI (ρ = 0.82, *P* \< 0.001), BASFI (ρ = 0.66, *P* \< 0.001), and ASDAS (ρ = 0.76, *P* \< 0.001) (Table [2](#T2){ref-type="table"}, Fig.). These correlations were in the same range as correlations of BASDAI with ASDAS-ESR (ρ = 0.81) and ASDAS-CRP (ρ = 0.77) (Fig.).

###### 

Spearman Correlations of RAPID3 With AS Disease-Specific Composite and Individual Measures Including BASDAI, ASDAS, and BASFI
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![Correlation plots comparing scores for RAPID3 versus (A) BASDAI, (B) ASDAS-ESR, and (C) ASDAS-CRP with RAPID3, and (D) scores for BASDAI versus ASDAS-ESR. Note high correlations of these measures, in the same range for RAPID3 versus AS indices as for BASDAI versus ASDAS.](rhu-21-300-g003){#F1}

Correlations of RAPID3 were significant with individual responses on the BASDAI or BASFI for spinal pain (ρ = 0.75, *P* \< 0.001), spinal stiffness (ρ = 0.74, *P* \< 0.001), fatigue (ρ = 0.68, *P* \< 0.001), and physical function (ρ = 0.66, *P* \< 0.001) (Table [1](#T1){ref-type="table"}). Correlations of RAPID3 with physical measures of spinal mobility, or with acute-phase reactants ESR and CRP, were not statistically significant (Table [2](#T2){ref-type="table"}).

Overall, 20, 25, 23, and 37 patients had RAPID 3 scores indicating high, moderate, low severity, and remission, respectively, according to categories developed initially for RA.^[@R18]^ Interrater agreement of RAPID3 remission or not in remission with ASDAS inactive or active was significant (κ = 0.486, agreement = 77.8%, *P* \< 0.001), but low between RAPID3 remission or not in remission and BASDAI inactive or active (κ = 0.160, agreement = 45.6%, *P* = 0.002). However, all 20 patients with BASDAI scores of 4 or greater, indicating active AS, had RAPID3 scores of greater than 12, indicating high severity (Table [3](#T3){ref-type="table"}). Among 33 patients with ASDAS of greater than 1.3, indicating active disease, 26 (79%) had high severity according to RAPID3 (Table [3](#T3){ref-type="table"}).

###### 

Cross Tabulation of RAPID3 and BASDAI Severity Groups
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DISCUSSION
==========

The BASDAI, ASDAS, BASFI, and BASMI are standard disease-specific indices to assess the status of patients with AS. These indices may include measures from patient self-report, a health professional, and laboratory tests and are collected feasibly in clinical trials and other clinical research, as well as in routine care at a few sites with a special interest in AS. However, most routine clinical rheumatology care settings do not collect an index to assess RA quantitatively^[@R24]^; it appears unlikely that a site would collect a BASDAI in AS patients when RAPID3 is not collected in RA patients.

It is difficult to collect several different patient questionnaires from patients with different diagnoses in busy clinical settings.^[@R7]^ Furthermore, collection of several domains of ASDAS core data set measures and calculation of complex formulas for ASDAS are not feasible in all individual patients seen in routine care, despite an excellent Web site for calculation (<http://www.asas-group.org/research/asdas_calculator/asdas.html>). By contrast, it is rather simple for the clinic receptionist to distribute the same questionnaire to each patient upon registration at the clinic.^[@R7]^ This practice facilitates completion of the questionnaire by the patient in the waiting area and helps the patient prepare for the visit, so the information is available to both patient and rheumatologist at initiation of the encounter.^[@R7]^ Scoring of RAPID3 on an MDHAQ requires 5 seconds,^[@R18]^ and RAPID3 is useful in all rheumatic diseases in which it has been studied, including RA,^[@R11],[@R18],[@R21],[@R25]--[@R30]^ systemic lupus erythematosus,^[@R15],[@R22]^ psoriatic arthritis,^[@R13]^ gout,^[@R13]^ vasculitis,^[@R23]^ osteoarthritis, and AS.^[@R14]--[@R16]^ RAPID3 is feasible in assessing disease severity and improvement in routine clinical of RA and is similar to DAS28 and Clinical Disease Activity Index (CDAI) to distinguish active from control treatments in RA trials of adalimumab, abatacept, and certolizumab.^[@R31]^

The limited feasibility of collecting BASDAI and ASDAS as 1 of several questionnaires in routine care usually leaves laboratory tests as the only quantitative data available for clinical decisions in the medical records of most patients with AS. However, laboratory tests often are not available at the time of the encounter and often are normal in patients with active clinical disease.^[@R5]^ Thus, improvement (or worsening) in AS patients is characterized only by narrative descriptions, rather than by quantitative clinical data.^[@R32]^

Several limitations are seen to this study. First, it is cross sectional; longitudinal studies extending a recently published small series including AS over a short period^[@R13]^ would be desirable in clinical trials and usual care. Second, low κ's between RAPID3 and BASDAI, although statistically significant, were not as strong as might be ideal, explained in part by the presence of joint damage and/or concomitant fibromyalgia in patients who do not have active disease on physical examination. This phenomenon has been documented to be a significant issue with DAS28 and CDAI in RA,^[@R33]^ in which patients with scores indicating moderate or severe activity did not have intensification of therapy, explained in large part by joint damage and fibromyalgia.^[@R34]^ In our study, all 21 patients with BASDAI of 4 or greater, indicating active disease, had RAPID3 of greater than 12, indicating high severity. RAPID3 is thus effective to provide the most important goal of recognizing patients with severe disease activity who may require intensification of treatment, particularly in the era of anti--tumor necrosis factor agents, although some of these patients may not require aggressive anti-inflammatory therapy.

A third possible limitation is that RAPID3 was not correlated significantly with metrology scores or laboratory tests. However, low correlations of patient indices with laboratory tests and imaging data are seen in RA. For example, a CDAI is as effective to document changes in status as a Simplified Disease Activity Index, which includes an ESR or CRP.^[@R35]^ Of course, AS-specific spinal flexibility measures are informative in clinical trials and other research and valuable in development of improved treatments, but may not be required in usual care.

A fourth possible limitation is that highly significant correlations do not necessarily imply identity of information contained in 2 measures, as a line indicating near identity may not go through the origin at zero, but be shifted upward or downward. A shift upward is seen for correlations of RAPID3 (as well as BASDAI) with ASDAS scores. However, correlations of RAPID3 and BASDAI essentially go through the origin at zero. Furthermore, correlations of ρ = 0.8 are at a level seen in test-retest studies of the same measure,^[@R36]^ as high as seen in clinical medicine. Similar high correlations have been observed in 3 other settings in the United States,^[@R14]^ Turkey,^[@R15]^ and Norway,^[@R16]^ indicating great similarity of the information provided by the 2 questionnaires.

The authors do not advocate at all that RAPID3 should replace BASDAI, BASFI, ASDAS, or BASMI. Disease-specific indices are invaluable for research and development of new therapies. Furthermore, RAPID3 (or any index) must be supplemented by a standard medical history, physical examination, laboratory tests, and/or any other clinical information regarded as important by the rheumatologist in formulating clinical decisions. Collection of RAPID3 in no way precludes collection of BASDAI, ASDAS, or any other index. Nonetheless, RAPID3 is feasible in usual care^[@R7]^ and appears preferable to the absence of any quantitative clinical measure at all,^[@R32]^ as is the case for most AS patients seen by rheumatologists at this time. The MDHAQ/RAPID3 might be added to research protocols to provide information to facilitate quantitative clinical assessment in routine care of patients with AS.
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